Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Hangzhou Diagens Biotechnology Co., Ltd.

Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) Stock Overview

Explore Hangzhou Diagens Biotechnology Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.

2526.HK●HKSE
HealthcareMedical - Devices
HK$288.80
HK$41.20(12.48%)
Hong Kong Market opens in 44h 59m

Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK)

Meyka AI Score

Z

Key Financials

Market Cap25.7B
P/E RatioN/A
EPS (TTM)$-0.88
ROEN/A
Fundamental Analysis

AI Price Forecasts

1 Month$397.50
3 Months$284.72
1 Year Target$230.13

2526.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 38.96, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $230.13.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of N/A and a market capitalization of 25.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-12.48%
5-Day Change
-40.36%
1-Month Change
-9.30%
3-Month Change
2.34%
6-Month Change
37.79%
Year-to-Date (YTD) Change
37.79%
1-Year Change
37.79%
3-Year Change
37.79%
5-Year Change
37.79%
All-Time (Max) Change
37.79%

Contact Information

https://www.diagens.com
NaN
Room 101, Hangzhou, ZH, NaN

Company Facts

1,660 Employees
IPO DateMar 29, 2026
CountryCN
Actively Trading

Frequently Asked Questions